Tuesday, July 25, 2017

Nature Reviews Cancer contents August 2017 Volume 17 Number 8 pp451-580

If you are unable to see the message below, click here to view.

Nature Reviews Cancer

 
TABLE OF CONTENTS
 
August 2017 Volume 17 Number 8Advertisement
Nature Reviews Cancer cover
2016 2-year Impact Factor 37.147 Journal Metrics 2-year Median 28
In this issue
Research Highlights
Reviews
Perspectives

Also this month
 Featured article:
Drugging the 'undruggable' cancer targets
Chi V. Dang, E. Premkumar Reddy, Kevan M. Shokat & Laura Soucek

 
Open for Submissions

npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine. The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.

Explore the benefits of submitting your manuscript.

Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
 
Advertisement
Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved 
Join us September 25-28, 2017 in Atlanta, GA to advance the understanding of and, ultimately, help to eliminate the disparities in cancer that represent a major public health problem in our country... Learn more 
 
Advertisement
MEDTECH DEALMAKERS
A supplement to Nature Biotechnology | Nature Medicine | Nature Reviews Drug Discovery

Medtech Dealmakers explores the dealmaking strategies of the growing medical technology industry, and provides in-depth analysis of emerging technologies, as well as showcase innovative companies seeking partners. Check out the latest issue for medtech dealmaking and financing trends in 2016, and diagnostics deals from the past year- particularly for immuno oncology applications.

Download the issue for FREE
 
 
RESEARCH HIGHLIGHTS
Top

Tumour vaccines: Personal training by vaccination
p451 | doi:10.1038/nrc.2017.61
Two groups have shown that personalized, neoantigen-based tumour vaccines elicit effective T cell responses in patients with advanced melanoma, leading to favourable clinical outcomes. Combination with checkpoint blockade can be of additional benefit.
PDF


Pancreatic cancer: iExosomes target the 'undruggable'
p452 | doi:10.1038/nrc.2017.54
Kamerkar et al. have engineered exosomes that target KRASG12D (iExosomes) and have demonstrated the specificity and efficacy of iExosomes in targeting oncogenic KRAS in mouse models of pancreatic cancer.
PDF


Therapeutic resistance: Transcribing patterns of resistance
p452 | doi:10.1038/nrc.2017.59
Shaffer et al. analysed resistance in melanoma at the single-cell level and found that non-genetic, transcriptional variability in rare cells can predict the eventual emergence of drug resistance.
PDF


Immunotherapy: Keeping breast cancer in check
p454 | doi:10.1038/nrc.2017.55
Nolan et al. show that triple-negative breast cancers with BRCA1 mutations are immunogenic and susceptible to treatment with a combination of two checkpoint inhibitors and chemotherapy.
PDF


Chemotherapy: Neutrophils deliver the goods
p454 | doi:10.1038/nrc.2017.62
Neutrophils carrying liposomes that contain the antimitotic drug paclitaxel can penetrate the brain and suppress the recurrence of glioma in mice, thereby significantly improving survival.
PDF


Neuroblastoma: Tumours get super-enhanced
p455 | doi:10.1038/nrc.2017.56
Van Groningen et al. unravel the epigenetic nature of intratumoural heterogeneity in neuroblastoma, which comprises both lineage-committed adrenergic cells and undifferentiated mesenchymal cells that are defined by unique super-enhancer transcriptional networks and gene expression signatures.
PDF


Epigenetics: Therapy-induced transcription is cryptically widespread
p456 | doi:10.1038/nrc.2017.57
A new study demonstrates that DNA methyltransferase inhibitors and histone deacetylase inhibitors induce widespread cryptic transcription from transposable elements that may contribute to cancer immunogenicity.
PDF



IN BRIEF

Epigenetics: Tumour suppressive HIF2α | Tumour immunology: Feeding frenzy | Tumour immunology: Tumours copy to escape | Leukaemia: Multiple origins of relapse
PDF

Cancer
JOBS of the week
Post-Doctoral Fellow in Gut Microbiota and Colon Cancer
University of Toronto
Post Doc in Cell Signaling / Cancer Biology
Rutgers Cancer Institute of New Jersey
Assistant, Associate Professor for Cancer Biology Research
NYU Langone School of Medicine
Postdoctorial Fellowship - Department of Tumor Biology, Institute for Cancer Research
Oslo University Hospital
Postdoc or PhD Position in Cancer Research
University Medical Center Groningen (UMCG)
More Science jobs from
Cancer
EVENT
Winter Conference 2017: Diet, Nutrition and the Changing Face of Cancer Survivorship
05.12.17
London, UK
More science events from
Advertisement
An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation. 

Now open for submissions >> 
 
REVIEWS
Top
Microenvironmental regulation of tumour angiogenesis
Michele De Palma, Daniela Biziato & Tatiana V. Petrova
p457 | doi:10.1038/nrc.2017.51
This Review discusses the extrinsic regulation of angiogenesis by the tumour microenvironment, highlighting potential vulnerabilities that could be targeted to improve the applicability and reach of anti-angiogenic cancer therapies.
Abstract | Full Text | PDF

Novel insights into mesothelioma biology and implications for therapy
Timothy A. Yap, Joachim G. Aerts, Sanjay Popat & Dean A. Fennell
p475 | doi:10.1038/nrc.2017.42
Our understanding of mesothelioma pathobiology has increased dramatically in the past 5 years, with an improvement in our knowledge of mesothelioma genetics, epigenetics, tumour microenvironment and immunobiology. This Review discusses these advances and how they might affect therapeutic strategies.
Abstract | Full Text | PDF | Supplementary information

Advertisement
Single-cell biology 

Dissecting life's mysteries one cell at a time. 

Click to learn more.
 
PERSPECTIVES
Top
OPINION
Fragile sites in cancer: more than meets the eye
Thomas W. Glover, Thomas E. Wilson & Martin F. Arlt
p489 | doi:10.1038/nrc.2017.52
This Opinion article discusses recent studies that have provided new insights into the mechanisms of common fragile site instability and the resulting genomic effects, which include the generation of focal copy number alterations that affect the genomic landscape of many cancers.
Abstract | Full Text | PDF

VIEWPOINT
Drugging the 'undruggable' cancer targets
Chi V. Dang, E. Premkumar Reddy, Kevan M. Shokat & Laura Soucek
p502 | doi:10.1038/nrc.2017.36
In this Viewpoint article, we asked four scientists working to target important, but so-called 'undruggable', proteins in cancer for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of cancer research.
Abstract | Full Text | PDF

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: